There is no drug that can regenerate cartilage. There is no injection that can reverse osteoarthritis. Joint replacement — with all its surgical risk, recovery time, and limited lifespan — is the end of the road for most patients. A study published June 12, 2026, in the journal Science by researchers at Stanford Medicine aims to change all of that.
The study found that blocking a single aging-related protein — called 15-PGDH — restored lost cartilage in the knee joints of old mice, prevented arthritis from developing after joint injuries, and triggered cartilage regeneration in human tissue samples that had already progressed to joint replacement surgery. If the approach translates to humans, it could represent the first biological treatment capable of not just managing osteoarthritis but reversing it.
"Cartilage regeneration to such an extent in aged mice took us by surprise," said senior author Helen Blau, Ph.D., professor of microbiology and immunology and director of the Baxter Laboratory for Stem Cell Biology at Stanford Medicine. "The effect was remarkable. Imagine regrowing existing cartilage and avoiding joint replacement."
What 15-PGDH Is — and Why Blocking It Matters
The protein at the center of the study is 15-hydroxyprostaglandin dehydrogenase, known as 15-PGDH. According to ScienceDaily's coverage of the paper, the Stanford research team refers to 15-PGDH as a "gerozyme" — a class of proteins they first identified in 2023 that become more abundant as the body ages and contribute to declining tissue function throughout the body.
In prior work, the same Stanford team showed that 15-PGDH plays a central role in age-related muscle decline. When they blocked the protein in aging mice, older animals gained muscle mass and endurance. When they artificially elevated 15-PGDH in young mice, their muscles weakened and shrank. The protein has since been linked to regeneration in bone, nerve, and blood cells — suggesting it functions as a broad master regulator of tissue repair capacity across multiple organ systems.
In this new study, the researchers turned to cartilage — and found that it behaves differently from muscle, bone, and nerve. In most tissues, regeneration occurs through the activation and proliferation of stem cells. When 15-PGDH is blocked in muscle, stem cells reactivate and produce new muscle fibers. Cartilage appears to regenerate through a different mechanism: direct upregulation of cartilage-producing genes in existing chondrocytes (the cells responsible for cartilage production and maintenance).
When the researchers analyzed chondrocytes in treated mice using single-cell RNA sequencing, they found that the percentage of cells expressing cartilage-producing genes surged from 22% to 42% following 15-PGDH inhibition. According to WebProNews's analysis of the paper, treated old mice regained normal gait and weight-bearing, while untreated control mice developed osteoarthritis within weeks of the study period.
| Stanford 15-PGDH Cartilage Study Key Data | Detail |
| Published in | Science, June 12, 2026 |
| DOI | 10.1126/science.adx6649 |
| Led by | Helen Blau and Nidhi Bhutani, Stanford Medicine |
| Protein targeted | 15-PGDH (15-hydroxyprostaglandin dehydrogenase); a "gerozyme" |
| Mechanism | Blocks age-related suppressor of tissue repair capacity |
| Result in old mice | Reversed natural age-related cartilage loss; normal gait restored |
| Injury model result | Prevented osteoarthritis in 50% of cases after simulated ACL tear |
| Chondrocyte gene expression | Cartilage-producing cells increased from 22% to 42% |
| Human tissue result | Knee replacement samples began forming new functional cartilage in lab |
| Oral version status | Already in clinical trials for age-related muscle weakness |
| Existing OA treatments that regenerate cartilage | None approved |
| U.S. adults with osteoarthritis | ~32.5 million |
Three Experiments That Build the Case
The Stanford team conducted three distinct lines of investigation in this study, each building a stronger argument for clinical translation.
First — reversing age-related cartilage loss: In naturally aging old mice, a small-molecule 15-PGDH inhibitor injected into the knee joint reversed the cartilage loss that had accumulated over the animals' lifetimes. The cartilage that grew back was healthy, functional hyaline cartilage — the shock-absorbing type that osteoarthritis destroys — not fibrocartilage, the inferior scar tissue type that current regenerative approaches tend to produce.
Second — preventing post-injury osteoarthritis: In mice with simulated ACL-type knee injuries — the kind of sports injury that triggers a rapid slide toward osteoarthritis — twice-weekly inhibitor injections for four weeks after injury prevented osteoarthritis from developing in approximately 50% of treated animals. According to ScienceAlert's analysis, this is a particularly significant finding for athletes and recreational exercisers, who face roughly a 50% lifetime risk of developing osteoarthritis after ACL and significant knee injuries.
Third — human tissue response: This is the most clinically compelling finding. The researchers obtained cartilage samples from patients who had already progressed to knee replacement surgery — meaning their cartilage was so severely damaged that surgical removal was the chosen intervention. When those human samples were exposed to the 15-PGDH inhibitor in laboratory conditions, the tissue began producing new, functional cartilage within one week. The Stanford Report notes that this response occurred not from stem cells, but from the native chondrocytes already present in the degenerated tissue — reactivated by the removal of 15-PGDH's inhibitory influence.
The Path to Human Patients — Accelerated by Existing Trial Data
The most significant translational advantage of the 15-PGDH inhibitor is that a version of this compound is already in human clinical trials. According to ScienceAlert, a prior clinical trial of a 15-PGDH blocker for age-related muscle weakness did not raise any safety or health concerns — providing an existing human safety dataset that typically requires years of Phase 1 trial work to develop from scratch for a new compound.
"Our hope is that a similar trial will be launched soon to test its effect in cartilage regeneration. We are very excited about this potential breakthrough," Dr. Blau stated in ScienceDaily.
The inhibitor has been licensed to a biotechnology company. The specific company was not named in available coverage, but the licensing suggests commercial development is underway.
For the approximately 32.5 million Americans living with osteoarthritis — and the millions more who will develop it as the population ages — this study provides the first biological proof of concept that lost cartilage can be restored through a pharmacological approach. No treatment on the current market slows or reverses cartilage loss. All current osteoarthritis treatment is symptom management: pain medication, physical therapy, corticosteroid or hyaluronic acid injections, and ultimately joint replacement surgery. The 15-PGDH inhibitor, if it succeeds in clinical trials, would be the first disease-modifying treatment for osteoarthritis — a category that has not yet existed.
Frequently Asked Questions
What did the Stanford arthritis study find?
Published in Science on June 12, 2026, the Stanford Medicine study found that blocking an aging-related protein called 15-PGDH reversed natural cartilage loss in old mice, prevented post-injury arthritis from developing, and triggered cartilage regeneration in human knee tissue from joint replacement surgeries.
What is 15-PGDH and why does blocking it regrow cartilage?
15-PGDH is a "gerozyme" — a protein whose levels increase with age and suppress the body's tissue repair capacity. By inhibiting this protein, the Stanford team removed a brake on the cartilage-producing cells (chondrocytes) already present in the joint, allowing them to reactivate and produce new, functional cartilage.
Did this work in human tissue?
Yes — in laboratory experiments. Human cartilage samples taken from knee replacement surgeries (already severely degenerated) began producing new cartilage after one week of exposure to the 15-PGDH inhibitor. This is a highly promising finding but does not yet represent human clinical trial data.
When could this be available to patients?
Human clinical trials for cartilage regeneration have not yet been formally announced, though Dr. Blau said the team hopes to launch one soon. An oral version of the compound is already in trials for muscle weakness, providing existing safety data. Timeline to patient availability would depend on the design and results of future trials — likely several years minimum.
What are the current treatment options for osteoarthritis?
Current options are limited to symptom management: anti-inflammatory medications (NSAIDs), corticosteroid injections, hyaluronic acid injections, physical therapy, and ultimately total joint replacement. No currently approved treatment slows or reverses cartilage loss.
.jpeg?w=600)
